Evidence map›Paper›PMID 34321608›Full record

ArticleThe Journal of antibiotics2021

Androprostamine A: a unique antiprostate cancer agent.

Yohko Yamazaki, Hikaru Abe, Chiharu Sakashita, Shun-Ichi Ohba, Takumi Watanabe, Isao Momose, Manabu Kawada

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yohko YamazakiInstitute of Microbial Chemistry (BIKAKEN), Numazu Branch, Numazu, Shizuoka, 410-0301, Japan. yamako@bikaken.or.jp.
Hikaru AbeInstitute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, 141-0021, Japan.
Chiharu SakashitaInstitute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, 141-0021, Japan.
Shun-Ichi OhbaInstitute of Microbial Chemistry (BIKAKEN), Numazu Branch, Numazu, Shizuoka, 410-0301, Japan.
Takumi WatanabeInstitute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, 141-0021, Japan.
Isao MomoseInstitute of Microbial Chemistry (BIKAKEN), Numazu Branch, Numazu, Shizuoka, 410-0301, Japan.ORCID http://orcid.org/0000-0002-9867-3881
Manabu KawadaInstitute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, 141-0021, Japan.ORCID http://orcid.org/0000-0001-9348-4240
Microbial Chemistry Research Foundation · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The androgen receptor (AR) is an important therapeutic target for all clinical states of prostate cancer. We screened cultured broths of microorganisms for their ability to suppress androgen-dependent growth of human prostate cancer LNCaP and VCaP cells without cytotoxicity. We have already identified androprostamine A (APA) from a Streptomyces culture broth as a functional inhibitor of AR. APA repressed R1881 (the synthetic androgen methyltrienolone)-induced androgen-regulated gene expression and dramatically inhibited R1881-induced prostate-specific antigen levels. However, APA did not act as an AR antagonist and did not inhibit AR transcriptional activity. Moreover, AS2405, an APA derivative, significantly inhibited the growth of VCaP cells in SCID mice upon oral administration.

Indexed as

Antineoplastic AgentsCell Line, TumorCell SurvivalCinnamatesGene Expression Regulation, NeoplasticHumansMaleMolecular StructureOligopeptidesProstatic NeoplasmsStreptomycesandroprostamine AAntineoplastic AgentsCinnamatesOligopeptides

Identifiers

PMID34321608
OpenAlexW3186669557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.